6FXN image
Deposition Date 2018-03-09
Release Date 2018-04-04
Last Version Date 2024-11-20
Entry Detail
PDB ID:
6FXN
Keywords:
Title:
Crystal structure of human BAFF in complex with Fab fragment of anti-BAFF antibody belimumab
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.90 Å
R-Value Free:
0.23
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 1 21 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Tumor necrosis factor ligand superfamily member 13B
Gene (Uniprot):TNFSF13B
Mutagens:H218A
Chain IDs:A, B, C, J, K, L
Chain Length:164
Number of Molecules:6
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:belimumab heavy chain
Chain IDs:D, F, H, M, O, Q
Chain Length:225
Number of Molecules:6
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:belimumab light chain
Chain IDs:E, G, I, N, P, R
Chain Length:214
Number of Molecules:6
Biological Source:Homo sapiens
Primary Citation
A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors.
Nat Commun 9 1199 1199 (2018)
PMID: 29572442 DOI: 10.1038/s41467-018-03323-8

Abstact

The B cell survival factor (TNFSF13B/BAFF) is often elevated in autoimmune diseases and is targeted in the clinic for the treatment of systemic lupus erythematosus. BAFF contains a loop region designated the flap, which is dispensable for receptor binding. Here we show that the flap of BAFF has two functions. In addition to facilitating the formation of a highly active BAFF 60-mer as shown previously, it also converts binding of BAFF to TNFRSF13C (BAFFR) into a signaling event via oligomerization of individual BAFF-BAFFR complexes. Binding and activation of BAFFR can therefore be targeted independently to inhibit or activate the function of BAFF. Moreover, structural analyses suggest that the flap of BAFF 60-mer temporarily prevents binding of an anti-BAFF antibody (belimumab) but not of a decoy receptor (atacicept). The observed differences in profiles of BAFF inhibition may confer distinct biological and clinical efficacies to these therapeutically relevant inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback